Senaparib is a next-generation, highly potent PARP1/2 inhibitor developed by IMPACT Therapeutics.

Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.

Finotonlimab, developed by Sinocelltech, is a recombinant humanized anti-programmed death receptor-1 (PD-1) monoclonal antibody.

In January 2025, multiple antibody-based therapies received global regulatory approvals, offering new hope for the treatment of various diseases.

Efsubaglutide Alfa received its first regulatory approval in China on January 24, 2025, from the National Medical Products Administration (NMPA).

Garadacimab is an innovative, fully human IgG4 monoclonal antibody specifically designed to target activated Factor XII (FXIIa).

Datopotamab Deruxtecan (Dato-DXd) is a Trop-2-targeting antibody-drug conjugate (ADC) developed jointly by Daiichi Sankyo and AstraZeneca.

Recaticimab, a monoclonal antibody developed by Hengrui Medicine, was approved by the National Medical Products Administration (NMPA) in China on January 8, 2025.

In this article, we present a comprehensive overview of drugs that received their first global approvals in January 2025, along with an analysis of these therapies.

Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders.

In 2024, the range of diseases treated by globally approved new drugs was diverse, with cancer and rare diseases leading in the total number of new drug approvals.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.